Orthofix Medical Inc. (NASDAQ:OFIX) Receives Average Rating of "Hold" from Brokerages

Key Points

• Analyst consensus: Hold — Six analysts cover Orthofix (1 sell, 2 hold, 3 buy) with an average 12‑month price target of $17.25, amid recent target cuts by Canaccord and Stifel and mixed upgrades such as Wall Street Zen’s move to buy.
• Insider selling — CEO Massimo Calafiore sold 9,797 shares at $15.21 and CFO Julie Andrews sold 4,873 shares at $14.38; insiders sold 28,539 shares (~$421,845) in the last 90 days and now own 1.30% of the stock.
• Earnings miss and position — Orthofix reported ($0.06) EPS vs. $0.44 expected despite a slight revenue beat, trades around $11.72 with a ~$470M market cap, and analysts forecast -2.81 EPS for the fiscal year.

Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) has received a consensus recommendation of "Hold" from the six research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $17.25.

OFIX has been the subject of a number of research analyst reports. Canaccord Genuity Group reduced their target price on Orthofix Medical from $24.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, February 26th. Stifel Nicolaus lowered their price target on Orthofix Medical from $22.00 to $18.00 and set a "buy" rating on the stock in a report on Monday, March 9th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Orthofix Medical in a report on Thursday, January 22nd. TD Cowen initiated coverage on Orthofix Medical in a research report on Tuesday, January 27th. They issued a "hold" rating and a $14.00 target price for the company. Finally, Wall Street Zen upgraded shares of Orthofix Medical from a "hold" rating to a "buy" rating in a research note on Saturday, March 7th.

Insider Activity at Orthofix Medical

In other news, CEO Massimo Calafiore sold 9,797 shares of the business's stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $15.21, for a total transaction of $149,012.37. Following the completion of the transaction, the chief executive officer directly owned 217,237 shares of the company's stock, valued at $3,304,174.77. The trade was a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Julie Andrews sold 4,873 shares of the stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $14.38, for a total transaction of $70,073.74. Following the transaction, the chief financial officer owned 58,039 shares in the company, valued at approximately $834,600.82. This trade represents a 7.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 28,539 shares of company stock valued at $421,845 over the last ninety days. Company insiders own 1.30% of the company's stock.

Hedge Funds Weigh In On Orthofix Medical

Institutional investors and hedge funds have recently modified their holdings of the company. CWM LLC grew its holdings in shares of Orthofix Medical by 99.0% in the third quarter. CWM LLC now owns 1,920 shares of the medical device company's stock worth $28,000 after acquiring an additional 955 shares during the period. Gabelli Funds LLC lifted its holdings in Orthofix Medical by 0.4% in the fourth quarter. Gabelli Funds LLC now owns 235,303 shares of the medical device company's stock valued at $3,567,000 after acquiring an additional 1,000 shares during the period. Raymond James Financial Inc. boosted its position in Orthofix Medical by 1.5% in the third quarter. Raymond James Financial Inc. now owns 66,812 shares of the medical device company's stock worth $978,000 after purchasing an additional 1,000 shares during the last quarter. Amundi boosted its position in Orthofix Medical by 2.7% in the fourth quarter. Amundi now owns 41,527 shares of the medical device company's stock worth $630,000 after purchasing an additional 1,086 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Orthofix Medical by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company's stock valued at $335,000 after purchasing an additional 1,213 shares during the period. 89.76% of the stock is currently owned by hedge funds and other institutional investors.

Orthofix Medical Trading Down 1.3%

Shares of NASDAQ OFIX opened at $11.72 on Wednesday. The firm's 50 day moving average price is $13.03 and its 200-day moving average price is $14.43. Orthofix Medical has a 52-week low of $10.24 and a 52-week high of $17.00. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.43 and a current ratio of 2.45. The company has a market cap of $470.44 million, a PE ratio of -5.01 and a beta of 0.75.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The medical device company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.44 by ($0.50). Orthofix Medical had a negative net margin of 11.21% and a negative return on equity of 20.38%. The firm had revenue of $219.91 million for the quarter, compared to the consensus estimate of $218.72 million. On average, equities research analysts expect that Orthofix Medical will post -2.81 EPS for the current fiscal year.

Orthofix Medical Company Profile

Orthofix Medical Inc NASDAQ: OFIX is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company's core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix's product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.